Eupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated by Analysts at Stifel Nicolaus

Stock analysts at Stifel Nicolaus started coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in a research report issued on Thursday,Benzinga reports. The brokerage set a “buy” rating and a $25.00 price target on the stock. Stifel Nicolaus’ price target would indicate a potential upside of 292.46% from the company’s current price.

EPRX has been the topic of a number of other research reports. HC Wainwright restated a “buy” rating and set a $11.00 target price on shares of Eupraxia Pharmaceuticals in a research report on Monday, May 4th. William Blair began coverage on shares of Eupraxia Pharmaceuticals in a research report on Monday, March 23rd. They set an “outperform” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Tuesday, April 21st. Wall Street Zen lowered shares of Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, Zacks Research upgraded shares of Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $18.33.

Eupraxia Pharmaceuticals Trading Up 1.3%

NASDAQ EPRX opened at $6.37 on Thursday. The stock has a market capitalization of $384.94 million, a P/E ratio of -6.07 and a beta of 1.19. Eupraxia Pharmaceuticals has a 52-week low of $3.67 and a 52-week high of $9.32. The firm has a 50-day moving average price of $7.20 and a 200 day moving average price of $7.32. The company has a quick ratio of 19.31, a current ratio of 19.31 and a debt-to-equity ratio of 0.02.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its earnings results on Tuesday, May 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). Equities research analysts expect that Eupraxia Pharmaceuticals will post -0.85 EPS for the current year.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. Bank of America Corp DE increased its stake in Eupraxia Pharmaceuticals by 5.9% during the 1st quarter. Bank of America Corp DE now owns 268,221 shares of the company’s stock worth $1,942,000 after buying an additional 14,900 shares during the period. Ally Bridge Group NY LLC increased its stake in Eupraxia Pharmaceuticals by 66.0% during the 1st quarter. Ally Bridge Group NY LLC now owns 660,375 shares of the company’s stock worth $4,781,000 after buying an additional 262,480 shares during the period. Royal Bank of Canada increased its stake in Eupraxia Pharmaceuticals by 33.2% during the 1st quarter. Royal Bank of Canada now owns 261,376 shares of the company’s stock worth $1,893,000 after buying an additional 65,099 shares during the period. Redmile Group LLC purchased a new stake in Eupraxia Pharmaceuticals during the 1st quarter worth $5,068,000. Finally, Rubric Capital Management LP purchased a new stake in Eupraxia Pharmaceuticals during the 1st quarter worth $5,004,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.